Comparative Pharmacology
Head-to-head clinical analysis: KLOR CON M20 versus KLOTRIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KLOR CON M20 versus KLOTRIX.
KLOR-CON M20 vs KLOTRIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium is the major intracellular cation; it is essential for the maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, and maintenance of acid-base balance. Potassium replacement therapy corrects hypokalemia.
KLOTRIX is a combination of an angiotensin II receptor blocker (ARB) and a thiazide diuretic. The ARB component blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor, leading to vasodilation and reduced blood pressure. The thiazide diuretic increases sodium and water excretion by inhibiting the sodium-chloride cotransporter in the distal convoluted tubule of the kidney.
20 mEq potassium chloride orally once daily, adjusted based on serum potassium levels and patient response. Maximum rate of administration: 20 mEq per hour if intravenous; oral doses divided if >20 mEq per dose.
Adults: 500-1000 mg orally every 6 hours; maximum 4000 mg/day.
None Documented
None Documented
The terminal elimination half-life of potassium is approximately 8-12 hours in healthy individuals, but is prolonged in renal impairment.
Terminal half-life 12 hours; prolonged to 24–30 hours in moderate renal impairment (CrCl <50 mL/min)
Potassium is primarily excreted renally (approximately 90%) as potassium ion in urine. A small amount is excreted in feces (about 10%).
Renal 70% as unchanged drug, fecal 30% via biliary secretion
Category C
Category C
Potassium Supplement
Potassium Supplement